Cardioprotective effect occurred in patients independently of blood sugar control
If approved semaglutide could become set the standard for GLP-1 therapy
Authors “optimistic” despite issues with front runners from AB Science and Otsuka
J&J taking on next gen drugs from Novartis, Eli Lilly, and Valeant.
Investors concerned over strong placebo effect
Companies hope tanezumab offers alternative to opioids
Lilly’s drug will be re-appraised in 2020